Is Aprepitant Oral Powder for Suspension (Emend) in shortage?
Aprepitant Oral Powder for Suspension is listed by FDA as being discontinued by at least one maker (updated Apr 8, 2026).
Every listed package
FDA tracks shortages per package. What each maker reports, most recently updated first:
- Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03)
To be discontinued in approximately early-September 2026.
Maker contact: 800-672-6372
FDA recalls of Aprepitant
Recalls can cause or worsen a shortage. These FDA drug recalls share an active ingredient with Aprepitant Oral Powder for Suspension:
- Merck Sharp & Dohme LLC recalls Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme
- Mckesson Medical-Surgical Inc. Corporate Office recalls Aprepitant Capsule, USP, 40 mg, 1 capsule per unit dose package, Rx only, MFG: Sandoz Pharma, NDC 0781-2321-06
Aprepitant Oral Powder for Suspension shortage questions
Is Aprepitant Oral Powder for Suspension (Emend) in shortage?
Aprepitant Oral Powder for Suspension is listed by FDA as being discontinued by at least one maker (updated Apr 8, 2026).
What should I do if I can’t get Aprepitant Oral Powder for Suspension?
Don’t stop or ration it on your own. Ask your pharmacist whether another strength, package size or maker is in stock, and ask your prescriber about an alternative if none is.
Source: FDA Drug Shortages Database via openFDA. FDA notes that openFDA data is unvalidated and should not be used to make decisions about medical care; ask your pharmacist or prescriber before changing any medication. FDA Drug Shortages Database.